IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9556160 B1

PDFFull Text
Date of Patent:
Jan. 31, 2017

Filed:

Mar. 27, 2015

Guanidine compound

Applicant:

Astellas Pharma Inc., Tokyo, JP;

Inventors:

Kousei Yoshihara, Chuo-ku, JP;

Daisuke Suzuki, Chuo-ku, JP;

Susumu Yamaki, Chuo-ku, JP;

Hiroyoshi Yamada, Chuo-ku, JP;

Hisashi Mihara, Chuo-ku, JP;

Norio Seki, Chuo-ku, JP;

Assignee:

Astellas Pharma Inc., Tokyo, JP;

Attorney:

Oblon, McClelland, Maier & Neustadt, L.L.P.

Primary Examiner:

Robert Havlin

Int. Cl.
CPC ...
C07D 413/04 (2006.01); C07D 401/12 (2006.01); A61K 31/5377 (2006.01); A61K 31/4412 (2006.01); C07D 413/12 (2006.01); C07D 205/04 (2006.01); C07D 211/60 (2006.01); C07D 211/78 (2006.01); C07D 213/38 (2006.01); C07D 213/64 (2006.01); C07D 213/74 (2006.01); C07D 217/06 (2006.01); C07D 217/22 (2006.01); C07D 237/20 (2006.01); C07D 239/26 (2006.01); C07D 239/42 (2006.01); C07D 241/20 (2006.01); C07D 277/42 (2006.01); C07D 277/46 (2006.01); C07D 277/56 (2006.01); C07D 295/06 (2006.01); C07D 295/08 (2006.01); C07D 295/18 (2006.01); C07D 295/20 (2006.01); C07D 309/08 (2006.01); C07D 309/14 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 403/06 (2006.01); C07D 403/12 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 239/48 (2006.01); C07D 267/10 (2006.01); C07D 239/34 (2006.01); C07D 295/192 (2006.01);
U.S. Cl.
CPC ...
C07D 413/12 (2013.01); A61K 31/4412 (2013.01); C07D 205/04 (2013.01); C07D 211/60 (2013.01); C07D 211/78 (2013.01); C07D 213/38 (2013.01); C07D 213/64 (2013.01); C07D 213/74 (2013.01); C07D 217/06 (2013.01); C07D 217/22 (2013.01); C07D 237/20 (2013.01); C07D 239/26 (2013.01); C07D 239/34 (2013.01); C07D 239/42 (2013.01); C07D 239/48 (2013.01); C07D 241/20 (2013.01); C07D 267/10 (2013.01); C07D 277/42 (2013.01); C07D 277/46 (2013.01); C07D 277/56 (2013.01); C07D 295/06 (2013.01); C07D 295/08 (2013.01); C07D 295/18 (2013.01); C07D 295/192 (2013.01); C07D 295/20 (2013.01); C07D 309/08 (2013.01); C07D 309/14 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/06 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 413/04 (2013.01); C07D 413/14 (2013.01);
Abstract

[Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that the compound or a salt thereof of the present invention exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. In addition, the present invention relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound or a salt thereof of the present invention, and an excipient.

Find Patent Forward Citations

Loading…